Context Therapeutics CFO granted 275,000 stock options

Minai-Azary Jennifer Lynn reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Minai-Azary Jennifer Lynn reported acquisition or exercise transactions in this Form 4 filing.

Context Therapeutics Inc. reported an insider equity award to its Chief Financial Officer, Jennifer Lynn Minai-Azary. She received a stock option covering 275,000 shares of common stock as a grant, not an open-market purchase or sale.

According to the terms, the option vests over four years. 25% of the option vests and becomes exercisable on February 19, 2027, with the remaining balance vesting in equal monthly installments over the following three years, subject to her continued service with the company.

Insider Trade Summary

Grant/Award: 275,000 shares

Grant/Award 1 txn

Insider Minai-Azary Jennifer Lynn

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	275,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 275,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Context Therapeutics (CNTX) report for its CFO?

Context Therapeutics reported a stock option grant to CFO Jennifer Lynn Minai-Azary. She received an option for 275,000 shares of common stock as a compensation award, not an open-market trade, aligning her incentives with long-term company performance.

How many Context Therapeutics (CNTX) shares are covered by the new CFO option grant?

The new option grant to the CFO covers 275,000 shares of Context Therapeutics common stock. This option represents potential future ownership, subject to vesting over four years and her continued service with the company during that period.

What are the vesting terms of the CFO’s stock option at Context Therapeutics (CNTX)?

The stock option vests over four years. Twenty-five percent vests and becomes exercisable on February 19, 2027, with the remaining seventy-five percent vesting in equal monthly installments over the next three years, contingent on continued service with Context Therapeutics.

Is the Context Therapeutics (CNTX) CFO’s Form 4 transaction a share purchase or sale?

The reported Form 4 transaction is an acquisition of a stock option grant, not a market purchase or sale of shares. It reflects compensation in the form of options that may be exercised in the future as they vest.

What conditions apply to the Context Therapeutics (CNTX) CFO’s new stock option grant?

The option vests and becomes exercisable only if the CFO continues serving Context Therapeutics. Vesting is 25% on February 19, 2027, and the remaining 75% vests monthly over three additional years, tying the award to ongoing employment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Minai-Azary Jennifer Lynn

(Last) (First) (Middle)

2001 MARKET STREET

SUITE 3915, UNIT #15

(Street)

PHILADELPHIA PA 19103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Context Therapeutics Inc. [ CNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.32	02/19/2026		A		275,000		(1)	02/18/2036	Common Stock	275,000	$0	275,000	D

Explanation of Responses:

1. The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Remarks:

	/s/ Alex Levit, Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.